Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.61 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703106 | 1.00 | PIM1 (0.61) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL704231 | 0.80 | PIM2 (0.74) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL704232 | 0.80 | PIM2 (0.74) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL700876 | 0.78 | PIM1 (0.62) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL700877 | 0.78 | PIM1 (0.62) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL700875 | 0.78 | PIM1 (0.62) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL10091751 | 0.78 | PIM1 (0.62) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL10091652 | 0.78 | PIM1 (0.59) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL701167 | 0.78 | PIM1 (0.59) | PIM1PIM2RPS6KA3PTPN1PTPN2 | |
| SCHEMBL701168 | 0.78 | PIM1 (0.59) | PIM1PIM2RPS6KA3PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307421-A1 | OXINDOLE COMPOUNDS | Cylene Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041635-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PIM2 3/4885RPS6KA3 290/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885PIM2 3/4885RPS6KA3 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.